Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Has results × Salivary Gland Neoplasms × pertuzumab × Clear all

Sponsor

Conditions

Breast Neoplasms 41 Ovarian Neoplasms 4 Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Solid Tumor 2 Rectal Neoplasms 2 Prostatic Neoplasms 2 Neoplasm Metastasis 2 Inflammatory Breast Neoplasms 2 HER2-positive Breast Cancer 2 Colonic Neoplasms 2 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Patient Preference 1 Pancreatic Neoplasms 1 Neuroendocrine Tumors 1 Neuroblastoma 1 Neoplasms, Unknown Primary 1 Multiple Endocrine Neoplasia 1 Malignant Solid Neoplasm 1 Lung Neoplasms 1 Locally Advanced Breast Cancer 1 Her2-Positive Breast Cancer 1 HER2-positive Metastatic Breast Cancer 1 HER2-positive Early Breast Cancer 1 Fallopian Tube Neoplasms 1 Carcinoma, Neuroendocrine 1 Carcinoid Tumor 1 Breast Neoplasms, Male 1 Biliary Tract Neoplasms 1

Interventions

Cetuximab 3 Vorinostat 2 Radiosurgery 2 Nivolumab 2 Ipilimumab 2 Dasatinib 2 Cisplatin 2 Bevacizumab 2 temsirolimus 1 pembrolizumab 1 ispinesib 1 eribulin 1 dehydroftorafur 1 apalutamide 1 alectinib 1 Sorafenib 1 Sirolimus 1 Platinum 1 Pilocarpine 1 Oral Hygiene 1 N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 1 Moxibustion 1 Magnetic Resonance Spectroscopy 1 MK 2206 1 Lapatinib 1 Irinotecan 1 Immunoglobulin G 1 Gonadotropin-Releasing Hormone 1 Gemcitabine 1 Gefitinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡